Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by houbahopon Mar 18, 2022 4:38am
164 Views
Post# 34524301

RE:THTX failure

RE:THTX failureAnd as the stock price slowly falls toward $1, you will see how posters on this
forum will evolve according to the normal reactions to a neurotic entity.

The only ones to blame are the investors supporting this kind of culture by
keeping the BOD in place. The fiduciary relationship between the directors
and their shareholders as been ignored for decades and it will remain like this
until the end. There are no surprises here.

This company has survived for 25 years at a cost of $335m and counting.
Some good research and good marketing/administration salaries have been financed with this, but unfortunately, it failed to show any kind of value to its shareholders.

Not too sure about the science discussion being worthless. It is clear some here found some value debating research. But for the vast majority of investors, TH is a horse that will burn you and that explains why there is no interest on the stock.

Don't try to sell another 50k of shares, it will bring the stock price below $3. 

<< Previous
Bullboard Posts
Next >>